Renaissance Technologies’s Enanta Pharmaceuticals ENTA Stock Holding History

Renaissance Technologies’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.4M	Buy	665,258 +23,058	+4%	+$309K	0.01%	1065
2025 Q4	$10.1M	Buy	642,200 +162,600	+34%	+$2.07M	0.02%	910
2025 Q3	$5.74M	Buy	479,600 +10,100	+2%	+$80.7K	0.01%	1409
2025 Q2	$3.55M	Buy	469,500 +5,900	+1%	+$35.5K	﹤0.01%	1741
2025 Q1	$2.56M	Sell	463,600 -34,400	-7%	-$212K	﹤0.01%	1848
2024 Q4	$2.86M	Sell	498,000 -26,900	-5%	-$258K	﹤0.01%	1812
2024 Q3	$5.44M	Buy	524,900 +14,000	+3%	+$183K	0.01%	1392
2024 Q2	$6.63M	Sell	510,900 -15,200	-3%	-$205K	0.01%	1135
2024 Q1	$9.19M	Sell	526,100 -32,400	-6%	-$429K	0.01%	1037
2023 Q4	$5.25M	Buy	558,500 +100,400	+22%	+$935K	0.01%	1314
2023 Q3	$5.12M	Sell	458,100 -18,200	-4%	-$293K	0.01%	1295
2023 Q2	$10.2M	Buy	476,300 +48,836	+11%	+$1.44M	0.01%	1013
2023 Q1	$17.3M	Sell	427,464 -45,736	-10%	-$2.18M	0.02%	799
2022 Q4	$22M	Buy	473,200 +5,200	+1%	+$237K	0.03%	656
2022 Q3	$24.3M	Sell	468,000 -74,800	-14%	-$4.37M	0.03%	582
2022 Q2	$25.7M	Sell	542,800 -64,300	-11%	-$3.49M	0.03%	610
2022 Q1	$43.2M	Sell	607,100 -107,300	-15%	-$6.98M	0.05%	392
2021 Q4	$53.4M	Sell	714,400 -42,185	-6%	-$3.31M	0.07%	320
2021 Q3	$43M	Sell	756,585 -41,143	-5%	-$2.03M	0.06%	364
2021 Q2	$35.1M	Sell	797,728 -102,472	-11%	-$5.02M	0.04%	464
2021 Q1	$44.4M	Sell	900,200 -133,700	-13%	-$6.67M	0.06%	395
2020 Q4	$43.5M	Buy	1,033,900 +4,900	+0.5%	+$216K	0.05%	401
2020 Q3	$47.1M	Buy	1,029,000 +86,100	+9%	+$4.17M	0.05%	402
2020 Q2	$47.3M	Buy	942,900 +62,300	+7%	+$3.22M	0.04%	445
2020 Q1	$45.3M	Buy	880,600 +149,000	+20%	+$7.94M	0.04%	423
2019 Q4	$45.2M	Buy	731,600 +68,700	+10%	+$4.26M	0.03%	571
2019 Q3	$39.8M	Buy	662,900 +112,600	+20%	+$8.36M	0.03%	587
2019 Q2	$46.4M	Sell	550,300 -95,205	-15%	-$8.56M	0.04%	524
2019 Q1	$61.7M	Sell	645,505 -151,695	-19%	-$13.6M	0.06%	423
2018 Q4	$56.5M	Sell	797,200 -51,200	-6%	-$3.93M	0.06%	372
2018 Q3	$72.5M	Sell	848,400 -30,100	-3%	-$3.02M	0.07%	311
2018 Q2	$102M	Buy	878,500 +33,600	+4%	+$3.35M	0.11%	199
2018 Q1	$68.4M	Buy	844,900 +73,300	+9%	+$5.64M	0.07%	324
2017 Q4	$45.3M	Buy	771,600 +90,500	+13%	+$4.53M	0.05%	496
2017 Q3	$31.9M	Buy	681,100 +60,600	+10%	+$2.44M	0.04%	627
2017 Q2	$22.3M	Buy	620,500 +52,807	+9%	+$1.69M	0.03%	783
2017 Q1	$17.5M	Sell	567,693 -7,078	-1%	-$220K	0.02%	882
2016 Q4	$19.3M	Sell	574,771 -126,629	-18%	-$3.63M	0.03%	812
2016 Q3	$18.7M	Buy	701,400 +549,200	+361%	+$12.8M	0.03%	750
2016 Q2	$3.36M	Buy	152,200 +96,600	+174%	+$2.53M	0.01%	1879
2016 Q1	$1.63M	Buy	+55,600	New	+$1.55M	﹤0.01%	2340
2014 Q4	–	Sell	-83,277	Closed	-$3.29M	–	3003
2014 Q3	$3.29M	Buy	83,277 +28,677	+53%	+$1.14M	0.01%	1389
2014 Q2	$2.35M	Buy	+54,600	New	+$2.08M	0.01%	1646
2014 Q1	–	Sell	-64,300	Closed	-$1.75M	–	2886
2013 Q4	$1.75M	Buy	+64,300	New	+$1.56M	﹤0.01%	1820

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies's ENTA Position: Q1 2026 in Review

Renaissance Technologies increased its Enanta Pharmaceuticals (ENTA) stake by 3.6% in Q1 2026, buying an estimated $309K and bringing the position to 665,258 shares worth $8.4M. The position accounts for 0.01% of the portfolio, ranked #1065.

Renaissance Technologies first reported a position in ENTA in Q4 2013 and has held it in 44 quarters since. The position peaked at $102M in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

Renaissance Technologies held 665,258 shares of Enanta Pharmaceuticals worth $8.4M as of Q1 2026.
Renaissance Technologies bought 23,058 Enanta Pharmaceuticals shares in Q1 2026, an estimated $309K.
Enanta Pharmaceuticals made up 0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1065 holding.
Renaissance Technologies first reported a position in Enanta Pharmaceuticals in Q4 2013 and has held it in 44 quarters since.
Renaissance Technologies's Enanta Pharmaceuticals position peaked at $102M in Q2 2018.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.